These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10617792)

  • 21. Magnitude of IFN-gamma production in HIV-1-infected children is associated with virus suppression.
    Reuben JM; Lee BN; Paul M; Kline MW; Cron SG; Abramson S; Lewis D; Kozinetz CA; Shearer WT
    J Allergy Clin Immunol; 2002 Aug; 110(2):255-61. PubMed ID: 12170266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons.
    Bruisten SM; Reiss P; Loeliger AE; van Swieten P; Schuurman R; Boucher CA; Weverling GJ; Huisman JG
    AIDS Res Hum Retroviruses; 1998 Aug; 14(12):1053-8. PubMed ID: 9718120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3.
    Revicki DA; Swartz C; Wu AW; Haubrich R; Collier AC
    Antivir Ther; 1999; 4(1):35-44. PubMed ID: 10682127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency of cytokine-producing T cells in HIV-infected patients treated with stavudine, didanosine, and ritonavir.
    Levacher M; Bouscarat F; Landman R; Chau F; Damond F; Gaudebout C; Mathez D; Leibowitch J; Saimot AG; Sinet M
    AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1869-75. PubMed ID: 11118072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant human gamma interferon in human immunodeficiency virus-infected children: safety, CD4(+)-lymphocyte count, viral load, and neutrophil function (AIDS Clinical Trials Group Protocol 211).
    Shearer WT; Kline MW; Abramson SL; Fenton T; Starr SE; Douglas SD
    Clin Diagn Lab Immunol; 1999 May; 6(3):311-5. PubMed ID: 10225828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy.
    Sun H; Kim D; Li X; Kiselinova M; Ouyang Z; Vandekerckhove L; Shang H; Rosenberg ES; Yu XG; Lichterfeld M
    J Virol; 2015 Nov; 89(22):11284-93. PubMed ID: 26339043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients.
    Smith D; Hales G; Roth N; Law M; Ray J; Druett J; Mitchell J; Mills G; Doong N; Franklin R;
    HIV Clin Trials; 2001; 2(2):97-107. PubMed ID: 11590517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of TH1/TH2 cytokines in HIV infection.
    Romagnani S; Del Prete G; Manetti R; Ravina A; Annunziato F; De Carli M; Mazzetti M; Piccinni MP; D'Elios MM; Parronchi P
    Immunol Rev; 1994 Aug; 140():73-92. PubMed ID: 7821929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study.
    Jensen-Fangel S; Kirk O; Blaxhult A; Gerstoft J; Pedersen C; Black FT; Lundgren JD; Obel N
    HIV Clin Trials; 2001; 2(2):122-7. PubMed ID: 11590520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intracellular production of type I and type II cytokines during HIV-1 progression in Thai patients.
    Onlamoon N; Lerdwana S; Ratanasuwan W; Suwanagool S; Puthavathana P; Pattanapanyasat K
    Asian Pac J Allergy Immunol; 2003 Mar; 21(1):43-8. PubMed ID: 12931750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression.
    Angel JB; Parato KG; Kumar A; Kravcik S; Badley AD; Fex C; Ashby D; Sun E; Cameron DW
    J Infect Dis; 2001 Feb; 183(4):546-54. PubMed ID: 11170979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.
    Mocroft A; Phillips AN; Ledergerber B; Smith C; Bogner JR; Lacombe K; Wiercinska-Drapalo A; Reiss P; Kirk O; Lundgren JD;
    Antivir Ther; 2010; 15(4):563-70. PubMed ID: 20587849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy and tolerance of a combination of AZT, DDC, and saquinavir in patients infected with the human immunodeficiency virus].
    Soriano Vázquez V; Rodríguez-Rosado Martínez-Echevarría R; Jiménez-Nacher I; Valencia Ortega E; Moreno Celda V; González-Lahoz J
    Rev Clin Esp; 1998 Sep; 198(9):634-5. PubMed ID: 9803794
    [No Abstract]   [Full Text] [Related]  

  • 38. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent antiretroviral therapy predict sustained suppression of viral replication.
    Fransen S; Copeland KF; Smieja M; Smaill F; Rosenthal KL
    J Infect Dis; 2000 Feb; 181(2):505-12. PubMed ID: 10669333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
    AIDS; 1999 Apr; 13(5):565-73. PubMed ID: 10203381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.